Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) — Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the “Company” or “ZCT”), a medical device company developing a SMART, AI-driven FemTech device to revolutionize women’s health, today announced that Sophya Galper Komet, CFO, and Dr. Asher Holzer, Founder, will present live at the OTCQB Venture Virtual Investor Conference hosted by VirtualInvestorConferences.com, on August 7th , 2025.
DATE: August 7th  Â
TIME: 12:00 PM ET
LINK:Â Â REGISTER HERE
Available for 1×1 meetings: August 7 & 8, 2025
This will be a live, interactive online event where investors are invited to ask the Company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com.
Company Highlights
- Demonstrated 99.999% Candida elimination in 3 hours during POC testing, targeting FDA De Novo regulatory pathway
- Expanding global IP portfolio with patents filed in Europe, the United States, Brazil, and fully granted in South Africa
- Cross-listed on FSE and OTCQB, including recent DTC eligibility, broadening investor access
- In active discussions with major hospitals and U.S. pharmaceutical companies to support future clinical trials and commercialization
About Zero Candida Technologies
Zero Candida Technologies, Inc. is a publicly traded FemTech company pioneering innovative solutions to address unmet needs in women’s health. The Company is developing a SMART, tampon-like device that combines artificial intelligence and therapeutic blue light at a precise wavelength and intensity to effectively treat Vulvo-Vaginal Candidiasis (VVC) through personalized, at-home care. This condition affects approximately 75% of women worldwide, and recurrent cases (four or more episodes per year) are increasingly resistant to existing drug treatments, as the root cause remains poorly understood and inadequately addressed. With the VVC treatment market projected to exceed US $2B by 2030, Zero Candida is combining hybrid medicine and technology-based diagnostics to improve access for underserved populations and bring gynecology into the 21st century. To learn more, visit www.zero-candida.com
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
CONTACTS:
Zero Candida Technologies, Inc.
+1 (647) 874-3767
[email protected]
Virtual Investor Conferences
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
[email protected]